Stockscreener 앱 받기
0.1651
2.83%
-0.0048
시간 외 거래:
.17
0.0049
+2.97%
전일 마감가:
$0.1699
열려 있는:
$0.1694
하루 거래량:
4.56M
Relative Volume:
2.90
시가총액:
$30.22M
수익:
-
순이익/손실:
$-32.54M
주가수익비율:
-0.8255
EPS:
-0.2
순현금흐름:
$-29.06M
1주 성능:
-49.73%
1개월 성능:
-57.03%
6개월 성능:
-77.38%
1년 성능:
-78.61%
1일 변동 폭
$0.1529
$0.1801
1주일 범위
$0.1529
$0.3279
52주 변동 폭
$0.1529
$1.07
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
명칭
Citius Pharmaceuticals Inc
전화
(908) 967-6676
주소
11 COMMERCE DRIVE, CRANFORD, NJ
CTXR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CTXR | 0.1651 | 30.22M | 0 | -32.54M | -29.06M | -0.20 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-11-30 | 개시 | Maxim Group | Buy |
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
Citius Pharmaceuticals stock hits 52-week low at $0.16 - Investing.com
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Successful Closure of Offering - Defense World
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan
What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World
Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com South Africa
Citius Pharmaceuticals stock hits 52-week low at $0.31 - Investing.com
Equities Analysts Set Expectations for CTXR FY2024 Earnings - MarketBeat
What is HC Wainwright’s Forecast for CTXR Q1 Earnings? - Defense World
Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com
Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia
Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat
Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - The Malaysian Reserve
Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma
Citius Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Citius Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com UK
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Is Breakeven Near? - Simply Wall St
Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India
CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com
Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Closing Bell Recap: Citius Pharmaceuticals Inc (CTXR) Ends at 0.37, Reflecting a -8.22 Downturn - The Dwinnex
There is no way Citius Pharmaceuticals Inc (CTXR) can keep these numbers up - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.39 By Investing.com - Investing.com Australia
Citius Pharmaceuticals stock hits 52-week low at $0.39 - Investing.com
Analyzing the Impact of Earnings Reports on Citius Pharmaceuticals Inc Inc. (CTXR) Price Performance - The InvestChronicle
Is Citius Pharmaceuticals Inc (CTXR) a threat to investors? - US Post News
Market Resilience: Citius Pharmaceuticals Inc (CTXR) Finishes Weak at 0.43, Down -2.60 - The Dwinnex
Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Market Fluctuations - The InvestChronicle
Point72 DIFC Ltd Makes New $29,000 Investment in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Defense World
Citius Pharmaceuticals Inc (CTXR) can make a big difference with a little luck - SETE News
Citius Pharmaceuticals stock hits 52-week low at $0.48 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com
Post-Trade Analysis: Citius Pharmaceuticals Inc (CTXR) Climbs 0.95, Closing at 0.52 - The Dwinnex
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Sees Significant Decrease in Short Interest - MarketBeat
Citius Pharmaceuticals Inc’s results are impressive - US Post News
Citius Pharmaceuticals extends executive and warrant agreements - Investing.com India
Citius Pharmaceuticals extends executive and warrant agreements By Investing.com - Investing.com South Africa
BCA says a US recession remains the most likely outcome - Investing.com
Armistice Capital LLC Purchases New Position in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - MarketBeat
Financial Snapshot: Analyzing Citius Pharmaceuticals Inc (CTXR)’s Key Ratio Metrics - The Dwinnex
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
Citius Pharmaceuticals Inc (CTXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):